Live Breaking News & Updates on Arcus biosciences

Stay informed with the latest breaking news from Arcus biosciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Arcus biosciences and stay connected to the pulse of your community

Head-To-Head Analysis: Gilead Sciences (NASDAQ:GILD) versus Mesoblast (NASDAQ:MESO)

Gilead Sciences (NASDAQ:GILD – Get Free Report) and Mesoblast (NASDAQ:MESO – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends. Insider & Institutional Ownership 83.7% of Gilead Sciences shares […]

Melbourne , Victoria , Australia , Switzerland , California , United-states , Foster-city , Japan , Singapore , China , Complera-eviplera , Janssen-sciences-ireland-unlimited-company

Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $41.25

Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 […]

United-states , Zurcher-kantonalbank-zurich-cantonalbank , Juanc-jaen , Ae-wealth-management , Arcus-biosciences-company-profile , Gilead-sciences-inc , Securities-exchange-commission , Arcus-biosciences-inc , Bluepath-capital-management , Financial-group , Arcus-biosciences , Get-free-report

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Moderate Buy" from Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Moderate Buy" from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states , Jennifer-jarrett , Arcus-biosciences-inc , Securities-exchange-commission , Allspring-global-investments-holdings , Gilead-sciences-inc , Vanguard-group-inc , Spartan-fund-management-inc , Arcus-biosciences , Get-free-report , Truist-financial , Biosciences-trading-down

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Holli-kolkey , Zeva-wainberg , Terry-rosen , Yelenay-janjigian , Memorial-sloan-kettering-cancer-center , American-society-of-clinical-oncology , Arcus-biosciences-inc , Gilead-sciences , Gastrointestinal-oncology-program , Corporate-communications

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal cancers will be presented in a special ASCO plenary series rapid abstract update...

United-states , American , Terry-rosen , Gilead-sciences , Arcus-biosciences-inc , American-society-of-clinical-oncology , Arcus-biosciences , Clinical-oncology , Annual-meeting , Rapid-abstract-updates , Lung-cancer , Non-small-cell

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Host-conference-call , Discuss-first-quarter , Access-code , Arcus-biosciences , Arcus-bioscience ,

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management...

Arcus-biosciences , Access-code , Arcus-bioscience ,

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch Health Companies (BHC – Research Report) and Arcus Bio...

Douglas-miehm , Kaveri-pohlman , Bausch-health-companies , Lomb-corporation , Sonnet-biotherapeutics-holdings , Aurinia-pharmaceuticals , Janux-therapeutics-inc , Research-report , Arcus-biosciences , Health-companies , Strong-buy ,

Exelixis stock slips as Barclays downgrades (NASDAQ:EXEL)

Exelixis stock slips as Barclays downgrades (NASDAQ:EXEL)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Manhattan , New-york , United-states , Peter-lawson , Iovance-biotherapeutics , Barclays , Wall-street , Lower-manhattan , Equal-weight , Arcus-biosciences ,

Head-To-Head Analysis: Beam Therapeutics (NASDAQ:BEAM) versus Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD – Get Free Report) and Beam Therapeutics (NASDAQ:BEAM – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Earnings & Valuation This table compares Gilead Sciences […]

United-states , Foster-city , California , Cambridge , Cambridgeshire , United-kingdom , Massachusetts , Japan , Complera-eviplera , Apellis-pharmaceuticals , Arcellx-inc , Pfizer-inc